WO 03/078395

International application No.

PCT/SE 03/00443

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: CO7D 211/06, CO7D 413/06, CO7D 413/14, A61K 31/445, A61P 37/00, A61P 11/06, A61P 31/16
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07D, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, WPI DATA, PAJ, CHEM, ABS DATA

c. Docu	C. DOCUMENTS CONSIDERED TO BE RELEVANT			
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
Х	WO 0035877 A1 (DU PONT PHARMACEUTICALS COMPANY), 22 June 2000 (22.06.00), the claims	1-12		
A	WO 9508535 A1 (THE BOOTS COMPANY PLC), 30 March 1995 (30.03.95), page 10, line 28, the claims	1-12		
				
A	WO 9641631 A1 (ELI LILLY AND COMPANY), 27 December 1996 (27.12.96), page 16, line 19 - page 17, line 21	1-12		
-				

X Further documents are listed in the continuation of Box (X See patent family annex.		
*	Special categories of cited documents:	"T"	later document published after the international filing date or priority		
"A"	document defining the general state of the art which is not considered to be of particular relevance		date and not in conflict with the application but cited to understand the principle or theory underlying the invention		
"E"	earlier application or patent but published on or after the international filing date	"X"	document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive		
"L"			step when the document is taken alone		
	cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance: the claimed invention cannot be		
"0"	document referring to an oral disclosure, use, exhibition or other means		considered to involve an inventive step when the document is combined with one or more other such documents, such combination being objects to a companie will do in the documents.		
"P"	document published prior to the international filing date but later than the priority date claimed $% \left(1\right) =\left(1\right) +\left(1\right) $	"& "	being obvious to a person skilled in the art document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report			
26 May 2003			1 6 -06- 2003		
Name and mailing address of the ISA/		Authorized officer			
Swedish Patent Office					
Box 5055, S-102 42 STOCKHOLM		Gerd Strandell/BS			
Facsimile No. + 46 8 666 02 86		Telephone No. +46 8 782 25 00			

Form PCT/ISA/210 (continuation of second sheet) (July 1998)

International application No. PCT/SE 03/00443

	1.	-C1/3E 03/0	
C (Continu	nation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the releva	int passages	Relevant to claim No
A	WO 9310091 A2 (GLAXO GROUP LIMITED), 27 May 19 (27.05.93), RN 150072-09-6, page 69, line 2 line 25; page 54, line 14 - line 22	993 24 -	1-12
A	STN International, File CAPLUS, CAPLUS accession no. 1988:630911, Document no. 109:230911, I Jochen et al: "Lactones. XVIII. Synthesis of lactone-bridged 1,1-diarylpropanamines"; & Pharm. (Weinheim, Ger.) (1988), 321(8), 443	Lehmann, of Arch.	1-12
			·
	·		

Interactional application No. PCT/SE03/00443

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)			
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:				
1.	Claims Nos.: 12 because they relate to subject matter not required to be searched by this Authority, namely:			
	see next sheet			
2.	Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:			
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).			
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)			
This Inte	rnational Searching Authority found multiple inventions in this international application, as follows:			
1.	As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.			
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.			
3.	As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:			
4.	No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:			
Remark	on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.			

Claim 12 relates to methods of treatment of the human or animal body by surgery or by therapy or diagnostic methods practised on the human or animal body (Rule 39.1(iv)). Nevertheless, a search has been executed for this claim. The search has been based on the alleged effects of the compounds or compositions. These alleged effects must be well defined diseases or conditions. The expression "a chemokine mediated disease state" may relate to a number of different disorders and conditions, which can not be clearly defined by this expression. Thus, the search has mainly been restricted to the diseases mentioned in the description on pages 13 to 16.

Information on patent family members

29/04/03

International application No.
PCT/SE 03/00443

	nt document n search report		Publication date		Patent family member(s)	Publication date
WO	0035877	A1	22/06/00	AU CA EP US US US	2056800 A 2347912 A 1140834 A 6036057 A 6331545 B 2002119980 A	03/07/00 22/06/00 10/10/01 14/03/00 18/12/01 29/08/02
WO	95 0 8535 ·	A1	30/03/95	AU DE EP GB IL JP US ZA	7697394 A 69404158 D,7 0720602 A,8 9319534 D 111016 D 9505274 T 5760035 A 9407331 A	
MO	9641631	A1	27/12/96	AU EP	5966096 A 0747055 A	09/01/97 11/12/96
WO	9310091	A2	27/05/93	AP AP AU CN EP GB JP MX ZA DE EP SE JP NO US	330 A 9200447 D 2915892 A 1073169 A 0542363 A 0612313 A 9124221 D 103746 D 7501063 T 9206541 A 9208768 A 69219773 D, 0587709 A, 0587709 T3 9201052 D 7502071 T 934529 A 5516586 A	